Bryan Daehahn Choi, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Glioblastoma | 21 | 2024 | 3481 | 3.010 |
Why?
|
Antibodies, Bispecific | 7 | 2019 | 164 | 2.210 |
Why?
|
Brain Neoplasms | 27 | 2024 | 8863 | 2.060 |
Why?
|
Immunotherapy, Adoptive | 12 | 2024 | 1270 | 1.860 |
Why?
|
Neurosurgery | 4 | 2022 | 643 | 1.450 |
Why?
|
Glioma | 10 | 2024 | 3401 | 1.080 |
Why?
|
Education, Graduate | 2 | 2014 | 81 | 0.890 |
Why?
|
T-Lymphocytes | 16 | 2023 | 10180 | 0.750 |
Why?
|
Receptors, Antigen, T-Cell | 7 | 2024 | 2540 | 0.730 |
Why?
|
Immunotherapy | 17 | 2023 | 4445 | 0.710 |
Why?
|
Cancer Vaccines | 6 | 2016 | 1023 | 0.650 |
Why?
|
Spinal Neoplasms | 3 | 2020 | 760 | 0.610 |
Why?
|
Antigens, Neoplasm | 4 | 2019 | 1988 | 0.560 |
Why?
|
Foreign-Body Migration | 1 | 2018 | 222 | 0.550 |
Why?
|
Meningomyelocele | 1 | 2017 | 165 | 0.550 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2013 | 44 | 0.460 |
Why?
|
Granzymes | 2 | 2019 | 271 | 0.450 |
Why?
|
Academic Medical Centers | 2 | 2014 | 2759 | 0.450 |
Why?
|
Perforin | 1 | 2013 | 168 | 0.450 |
Why?
|
T-Lymphocytes, Regulatory | 5 | 2020 | 2988 | 0.440 |
Why?
|
Thoracic Vertebrae | 1 | 2017 | 608 | 0.440 |
Why?
|
Complementarity Determining Regions | 1 | 2013 | 149 | 0.440 |
Why?
|
Publications | 1 | 2015 | 195 | 0.430 |
Why?
|
Granuloma, Plasma Cell | 1 | 2013 | 84 | 0.430 |
Why?
|
Lateral Ventricles | 1 | 2013 | 146 | 0.420 |
Why?
|
Wounds, Gunshot | 1 | 2018 | 563 | 0.420 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2012 | 109 | 0.410 |
Why?
|
Education, Medical, Graduate | 3 | 2014 | 2291 | 0.410 |
Why?
|
Bibliometrics | 1 | 2015 | 339 | 0.400 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2019 | 1369 | 0.380 |
Why?
|
Monitoring, Intraoperative | 2 | 2021 | 957 | 0.380 |
Why?
|
Lymphocyte Activation | 7 | 2019 | 5524 | 0.360 |
Why?
|
Biomedical Research | 3 | 2014 | 3309 | 0.320 |
Why?
|
Tumor Escape | 1 | 2011 | 349 | 0.320 |
Why?
|
Central Nervous System Neoplasms | 3 | 2022 | 895 | 0.310 |
Why?
|
Publishing | 1 | 2015 | 833 | 0.310 |
Why?
|
Transduction, Genetic | 3 | 2020 | 913 | 0.280 |
Why?
|
Cell Line, Tumor | 9 | 2021 | 16689 | 0.260 |
Why?
|
Isocitrate Dehydrogenase | 5 | 2024 | 871 | 0.250 |
Why?
|
Astrocytoma | 2 | 2024 | 790 | 0.250 |
Why?
|
B-Cell Activating Factor | 2 | 2016 | 119 | 0.240 |
Why?
|
Motor Cortex | 1 | 2012 | 986 | 0.240 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2019 | 3557 | 0.240 |
Why?
|
Neurosurgical Procedures | 4 | 2022 | 2002 | 0.230 |
Why?
|
Humans | 58 | 2024 | 744343 | 0.230 |
Why?
|
Surface Plasmon Resonance | 2 | 2013 | 274 | 0.210 |
Why?
|
Dacarbazine | 3 | 2016 | 566 | 0.210 |
Why?
|
Lymphoma | 2 | 2022 | 1877 | 0.200 |
Why?
|
Chemokine CCL20 | 1 | 2021 | 64 | 0.200 |
Why?
|
Receptors, CCR6 | 1 | 2021 | 81 | 0.200 |
Why?
|
Efficiency | 2 | 2014 | 462 | 0.190 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2016 | 627 | 0.190 |
Why?
|
4-1BB Ligand | 1 | 2020 | 29 | 0.190 |
Why?
|
RNA, Small Cytoplasmic | 1 | 2020 | 21 | 0.190 |
Why?
|
Antigens, CD19 | 2 | 2022 | 380 | 0.190 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.180 |
Why?
|
Lentivirus | 2 | 2020 | 501 | 0.180 |
Why?
|
Single-Chain Antibodies | 3 | 2018 | 108 | 0.170 |
Why?
|
Protein Engineering | 2 | 2013 | 540 | 0.170 |
Why?
|
Animals | 21 | 2021 | 168757 | 0.160 |
Why?
|
Brain Mapping | 2 | 2021 | 6669 | 0.150 |
Why?
|
Career Choice | 2 | 2014 | 744 | 0.150 |
Why?
|
Internship and Residency | 2 | 2015 | 5788 | 0.150 |
Why?
|
Evoked Potentials, Motor | 1 | 2021 | 454 | 0.150 |
Why?
|
Surgery, Plastic | 2 | 2014 | 624 | 0.150 |
Why?
|
Health Resources | 1 | 2023 | 911 | 0.150 |
Why?
|
Mice | 14 | 2021 | 81183 | 0.150 |
Why?
|
Antibody Specificity | 3 | 2013 | 1095 | 0.140 |
Why?
|
Mice, Inbred NOD | 3 | 2019 | 1878 | 0.140 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2019 | 233 | 0.140 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 973 | 0.140 |
Why?
|
Up-Regulation | 2 | 2024 | 4217 | 0.140 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2024 | 4479 | 0.130 |
Why?
|
Fellowships and Scholarships | 2 | 2014 | 1076 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 578 | 0.120 |
Why?
|
Adoptive Transfer | 2 | 2014 | 844 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20129 | 0.120 |
Why?
|
Lymphocyte Depletion | 2 | 2013 | 608 | 0.120 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13102 | 0.120 |
Why?
|
Craniotomy | 2 | 2021 | 729 | 0.120 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1276 | 0.120 |
Why?
|
Lymphocyte Count | 1 | 2016 | 793 | 0.110 |
Why?
|
Chromatography | 1 | 2012 | 206 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 4 | 2017 | 35421 | 0.110 |
Why?
|
Mice, SCID | 2 | 2019 | 2716 | 0.110 |
Why?
|
Antibody Affinity | 1 | 2013 | 254 | 0.110 |
Why?
|
Indicators and Reagents | 1 | 2013 | 462 | 0.110 |
Why?
|
Flow Cytometry | 2 | 2013 | 5974 | 0.110 |
Why?
|
Neoplasms | 4 | 2018 | 21683 | 0.100 |
Why?
|
Chimera | 1 | 2013 | 485 | 0.100 |
Why?
|
Microsurgery | 1 | 2017 | 796 | 0.100 |
Why?
|
Alcohol Oxidoreductases | 1 | 2012 | 170 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1782 | 0.100 |
Why?
|
Convection | 1 | 2011 | 31 | 0.100 |
Why?
|
Antigen-Antibody Complex | 1 | 2013 | 517 | 0.100 |
Why?
|
Mutation | 6 | 2024 | 29786 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1692 | 0.100 |
Why?
|
Oncolytic Viruses | 1 | 2015 | 327 | 0.100 |
Why?
|
Immunotoxins | 1 | 2011 | 179 | 0.090 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 1801 | 0.090 |
Why?
|
Combined Modality Therapy | 2 | 2020 | 8642 | 0.090 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2013 | 1723 | 0.090 |
Why?
|
Tumor Microenvironment | 4 | 2024 | 3586 | 0.090 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7785 | 0.090 |
Why?
|
Standard of Care | 1 | 2013 | 564 | 0.090 |
Why?
|
Research Support as Topic | 1 | 2013 | 705 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2018 | 2455 | 0.080 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2529 | 0.080 |
Why?
|
Sequence Alignment | 1 | 2013 | 2256 | 0.080 |
Why?
|
Treatment Outcome | 8 | 2020 | 63114 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6538 | 0.080 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1038 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 3523 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 1 | 2018 | 4554 | 0.070 |
Why?
|
Models, Molecular | 2 | 2013 | 5456 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1821 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9239 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3143 | 0.070 |
Why?
|
Prognosis | 4 | 2019 | 29063 | 0.060 |
Why?
|
Antineoplastic Agents | 3 | 2013 | 13695 | 0.060 |
Why?
|
History, 21st Century | 1 | 2011 | 1534 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12788 | 0.060 |
Why?
|
Vaccines, Subunit | 2 | 2016 | 168 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 4262 | 0.060 |
Why?
|
Male | 10 | 2021 | 350118 | 0.060 |
Why?
|
Drug Delivery Systems | 2 | 2012 | 2219 | 0.060 |
Why?
|
History, 20th Century | 1 | 2011 | 2740 | 0.060 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 25043 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2019 | 11483 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2019 | 5181 | 0.050 |
Why?
|
United States | 2 | 2023 | 69872 | 0.050 |
Why?
|
Saccharomyces cerevisiae | 1 | 2012 | 2752 | 0.050 |
Why?
|
Female | 10 | 2019 | 380194 | 0.050 |
Why?
|
Biopsy | 1 | 2013 | 6756 | 0.050 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13815 | 0.050 |
Why?
|
Lymphopenia | 2 | 2013 | 285 | 0.050 |
Why?
|
Single-Cell Analysis | 2 | 2021 | 2183 | 0.050 |
Why?
|
Escherichia coli | 1 | 2012 | 4217 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 18111 | 0.050 |
Why?
|
Signal Transduction | 2 | 2020 | 23403 | 0.040 |
Why?
|
Neoplasm Transplantation | 2 | 2014 | 2085 | 0.040 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2019 | 87 | 0.040 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2021 | 243 | 0.040 |
Why?
|
Interleukin-2 | 2 | 2018 | 1904 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5510 | 0.040 |
Why?
|
K562 Cells | 1 | 2020 | 634 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11124 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2020 | 77449 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 12959 | 0.040 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2021 | 8428 | 0.040 |
Why?
|
Aged | 3 | 2019 | 163280 | 0.040 |
Why?
|
Drug Therapy | 1 | 2020 | 497 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2021 | 810 | 0.040 |
Why?
|
Immunity | 1 | 2023 | 1012 | 0.040 |
Why?
|
Antibodies | 2 | 2016 | 2460 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 7913 | 0.030 |
Why?
|
Spine | 1 | 2020 | 1144 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3508 | 0.030 |
Why?
|
Biocatalysis | 1 | 2012 | 167 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1613 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6314 | 0.020 |
Why?
|
Autoimmunity | 1 | 2019 | 1349 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4204 | 0.020 |
Why?
|
Radiosurgery | 1 | 2020 | 1329 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2016 | 1200 | 0.020 |
Why?
|
Catalytic Domain | 1 | 2012 | 698 | 0.020 |
Why?
|
Adolescent | 2 | 2019 | 85781 | 0.020 |
Why?
|
Middle Aged | 3 | 2019 | 213383 | 0.020 |
Why?
|
Oncolytic Virotherapy | 1 | 2015 | 498 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2727 | 0.020 |
Why?
|
Mentors | 1 | 2014 | 631 | 0.020 |
Why?
|
Organ Transplantation | 1 | 2019 | 1139 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2014 | 2088 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2018 | 6622 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2019 | 18029 | 0.020 |
Why?
|
Adult | 2 | 2019 | 214055 | 0.020 |
Why?
|
Liposomes | 1 | 2011 | 759 | 0.020 |
Why?
|
Protein Binding | 1 | 2019 | 9386 | 0.020 |
Why?
|
Antigens | 1 | 2013 | 1466 | 0.020 |
Why?
|
Brain | 1 | 2014 | 26385 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2133 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5655 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2011 | 2327 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2019 | 2957 | 0.020 |
Why?
|
Gadolinium | 1 | 2011 | 952 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3616 | 0.020 |
Why?
|
Skin | 1 | 2019 | 4364 | 0.020 |
Why?
|
Cytokines | 1 | 2019 | 7322 | 0.020 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 1017 | 0.020 |
Why?
|
Cell Line | 1 | 2019 | 15997 | 0.020 |
Why?
|
Data Collection | 1 | 2014 | 3341 | 0.020 |
Why?
|
Cell Membrane | 1 | 2014 | 3748 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 21746 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10481 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9727 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5882 | 0.010 |
Why?
|
Cell Movement | 1 | 2014 | 5217 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16365 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13284 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9734 | 0.010 |
Why?
|
Genetic Testing | 1 | 2013 | 3444 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12951 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 56430 | 0.010 |
Why?
|